Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Thus, BAY 80-6946 induced 100% complete tumor regression when dosed as a single agent every second day in rats bearing HER2-amplified and PIK3CA-mutated KPL4 breast tumors.
|
24170767 |
2013 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
AR levels were significantly higher in breast tumors with kinase domain PIK3CA mutations versus tumors that are wild type or with PIK3CA helical mutations (P = 0.017 and P < 0.0001, respectively).
|
19276248 |
2009 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
This provides a rationale for the combined targeting of p110α with IGF1R or p110β in patients with breast tumors harboring PIK3CA mutations.
|
27048245 |
2016 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
However, here we show through phosphoprotein profiling and functional genomic studies that many PIK3CA mutant cancer cell lines and human breast tumors exhibit only minimal AKT activation and a diminished reliance on AKT for anchorage-independent growth.
|
19573809 |
2009 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
For example, although signaling and metabolic profiles of breast tumors with PIK3CA or AKT1 mutations are, as expected, highly similar, they display markedly different, sometimes even opposite, profiles to those with ERBB2 or EGFR amplifications.
|
24166508 |
2014 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
PIK3CA mutations are not associated with altered sensitivity to preoperative anthracycline-based or taxane-based chemotherapies in ER-positive and ER-negative breast tumors.
|
18371219 |
2008 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Twenty-three (27%) of the 86 primary breast tumors contained PIK3CA mutations.
|
23184205 |
2012 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In pre-clinical models, co-existence of Human Epidermal Growth Factor Receptor-2 (HER2)-amplification and PI3K catalytic subunit (PIK3CA) mutations results in aggressive, anti-HER2 therapy-resistant breast tumors.
|
31219154 |
2019 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Additionally, associations were found for EGFR variations in lung tumors and PIK3CA variations in breast tumors.
|
31100334 |
2019 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Our results suggest that the PIK3CA H1047R oncogene targets a multipotent progenitor cell and, furthermore, show that this model recapitulates features of human breast tumors with PIK3CA H1047R.
|
21482677 |
2011 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
We identified a 20.6% (19 of 92) and 33.3% (5 of 15) PIK3CA somatic mutation frequency in primary breast tumors and cell lines, respectively.
|
16168105 |
2005 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients.
|
18183466 |
2008 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We screened papillary breast neoplasms for activating point mutations in PIK3CA, AKT1, and RAS protein-family members, which are common in invasive ductal carcinomas.
|
19898424 |
2010 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We found that activation of the latent Pik3ca(H1047R) allele resulted in breast tumors with multiple histological types.
|
22370636 |
2013 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
We identified PIK3CA mutations in 26% of 342 human breast tumor samples and cell lines at about equal frequency in tumor stages I to IV.
|
15805248 |
2005 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
All mutations were mutually exclusive, apart from one basal-like breast tumour which harboured mutations in both MET (p.T992I) and PIK3CA (p.H1047R).
|
24318467 |
2014 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
High frequency of PIK3CA mutations (28%) were also found in HER2+ breast tumors.
|
22538770 |
2012 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
PIK3CA mutations were observed in 23.2 % (43/185) of breast tumor samples.
|
27282497 |
2016 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors.
|
31139940 |
2020 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.
|
18679714 |
2008 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese.
|
16582596 |
2006 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
PIK3CA gene mutations in breast carcinoma in Malaysian patients.
|
19027487 |
2008 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We screened 250 primary human breast tumors for mutations in PIK3CA in order to determine associations with pathological features and with patient outcome.
|
16317585 |
2006 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
It is unknown whether changes in the PI3K pathway result in a different composition of the breast tumor microenvironment.
|
31391067 |
2019 |